These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29045532)

  • 1. Stevens-Johnson syndrome during nivolumab treatment of NSCLC.
    Salati M; Pifferi M; Baldessari C; Bertolini F; Tomasello C; Cascinu S; Barbieri F
    Ann Oncol; 2018 Jan; 29(1):283-284. PubMed ID: 29045532
    [No Abstract]   [Full Text] [Related]  

  • 2. Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer.
    Gracia-Cazaña T; Padgett E; Calderero V; Oncins R
    Dermatol Online J; 2021 Mar; 27(3):. PubMed ID: 33865285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab.
    Rouyer L; Bursztejn AC; Charbit L; Schmutz JL; Moawad S
    Eur J Dermatol; 2018 Jun; 28(3):380-381. PubMed ID: 29952288
    [No Abstract]   [Full Text] [Related]  

  • 4. [Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC): a case report].
    Tan KX; Li CY; Zhang JY; Cui HJ; Shen W; Zhang X; Sun CY; Jiang XJ; Zheng SY; Li J; Xue CX
    Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1047-1048. PubMed ID: 33342162
    [No Abstract]   [Full Text] [Related]  

  • 5. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma.
    Dasanu CA
    J Oncol Pharm Pract; 2019 Dec; 25(8):2052-2055. PubMed ID: 30782092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal Lichen Planus Mimicking Mucosal Lesions in Stevens-Johnson Syndrome after Nivolumab Therapy.
    Miyagawa F; Nakajima A; Ohyama SI; Aoki Y; Nishikawa M; Nakamura Y; Hashimoto T; Asada H
    Acta Derm Venereol; 2019 Jun; 99(7):687-688. PubMed ID: 30938822
    [No Abstract]   [Full Text] [Related]  

  • 7. Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
    Schouten RD; Muller M; de Gooijer CJ; Baas P; van den Heuvel M
    Lung Cancer; 2018 Dec; 126():210-216. PubMed ID: 29179916
    [No Abstract]   [Full Text] [Related]  

  • 8. Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1®) after nivolumab discontinuation.
    Komatsu-Fujii T; Ogawa M; Nonoyama S; Fukumoto T; Tanabe H
    Eur J Dermatol; 2021 Feb; 31(1):98-99. PubMed ID: 33586655
    [No Abstract]   [Full Text] [Related]  

  • 9. Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease.
    Guaitoli G; Baldessari C; Tomasello C; Barbieri F; Cascinu S; Bertolini F; Cesinaro AM
    J Thorac Oncol; 2018 Aug; 13(8):e152-e153. PubMed ID: 30049380
    [No Abstract]   [Full Text] [Related]  

  • 10. Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC.
    Callens R; Tamsin A; van Zandweghe L
    J Thorac Oncol; 2019 Mar; 14(3):e49-e50. PubMed ID: 30782382
    [No Abstract]   [Full Text] [Related]  

  • 11. Nivolumab-Associated Guillain-Barre Syndrome in a Patient With Non-Small-Cell Lung Cancer.
    Thapa B; Khalid S; Vakili R; Ui J; Misbah S
    Am J Ther; 2018; 25(6):e761-e763. PubMed ID: 29889678
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
    Sata M; Sasaki S; Oikado K; Saito Y; Tominaga J; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
    Cancer Sci; 2021 Apr; 112(4):1506-1513. PubMed ID: 33125784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.
    Facchinetti F; Gnetti L; Caruana P; Fornaroli F; Luigi de'Angelis G; Sabato M; Ferri L; Cosenza A; Bordi P; Tiseo M
    Clin Lung Cancer; 2018 Sep; 19(5):e591-e596. PubMed ID: 29801705
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
    Grossi F; Crinò L; Logroscino A; Canova S; Delmonte A; Melotti B; Proto C; Gelibter A; Cappuzzo F; Turci D; Gamucci T; Antonelli P; Marchetti P; Santoro A; Giusti S; Di Costanzo F; Giustini L; Del Conte A; Livi L; Giannarelli D; de Marinis F
    Eur J Cancer; 2018 Sep; 100():126-134. PubMed ID: 30014881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
    Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
    Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.
    Yano Y; Kurebe H; Edahiro R; Hosono Y; Nakatsubo S; Nishida K; Sawa N; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
    PLoS One; 2018; 13(8):e0203070. PubMed ID: 30153300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
    Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
    Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
    Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
    Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC.
    Kato R; Hayashi H; Sano K; Handa K; Kumode T; Ueda H; Okuno T; Kawakami H; Matsumura I; Kudo M; Nakagawa K
    J Thorac Oncol; 2018 Dec; 13(12):e239-e241. PubMed ID: 30017828
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
    Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
    Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.